Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8829602 | 1.00 | ADRB3 (0.70) | ADRB3ADRB1 | |
| SCHEMBL9483243 | 1.00 | ADRB3 (0.70) | ADRB3ADRB1 | |
| SCHEMBL6133378 | 1.00 | ADRB3 (0.70) | ADRB3ADRB1 | |
| SCHEMBL9006797 | 1.00 | ADRB3 (0.70) | ADRB3ADRB1 | |
| SCHEMBL5188566 | 1.00 | ADRB3 (0.70) | ADRB3ADRB1 | |
| SCHEMBL9006647 | 1.00 | ADRB3 (0.70) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL9317513 | 0.99 | ADRB3 (0.69) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL10799438 | 0.99 | ADRB3 (0.69) | ADRB3ADRB1 | |
| Bromide SCHEMBL10800802 | 0.99 | ADRB3 (0.69) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL9316504 | 0.99 | ADRB3 (0.69) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0403360-B1 | Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders | SANOFI SA (FR) | 1996-10-16 | — | — | EP | claimed |
| EP-0303546-B1 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI SA (FR) | 1994-12-28 | — | — | EP | claimed |
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ASTELLAS PHARMA INC. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1483236-A1 | AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076397-A1 | AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | WO | disclosed |
| EP-0403360-B1 | Use of phenylethanolamines for the preparation of a medicament for treating ophthalmologic disorders | SANOFI SA (FR) | 1996-10-16 | — | — | EP | disclosed |
| EP-0303546-B1 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI SA (FR) | 1994-12-28 | — | — | EP | disclosed |
| EP-0303545-B1 | PROCESS FOR THE PREPARATION OF PHENYLETHANOLAMINOTETRALINES | ELF SANOFI (FR) | 1992-06-17 | — | — | EP | disclosed |
| EP-0303546-A2 | O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines | SANOFI (FR) | 1989-02-15 | — | — | EP | disclosed |
| EP-0303545-A2 | Process for the preparation of phenylethanolaminotetralines | ELF SANOFI (FR) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009934-A1 | BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADRB1, ADRB2, ADRA2B | ADRB3 5/4885ADRB1 1/4885 |
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB3 3/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.